Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Previously presented) A method of reducing or inhibiting angiogenesis in a tissue, comprising contacting α5β1 integrin in the tissue with an agent, wherein said agent comprises an anti-α5β1 integrin antibody or an α5β1 integrin binding fragment of said antibody, and said agent interferes with specific binding of the α5β1 integrin to fibronectin expressed in the tissue, thereby reducing or inhibiting angiogenesis in the tissue.

Claim 2 (Canceled).

Claim 3 (Canceled).

4. (Original) The method of claim 1, wherein the tissue comprises ocular tissue.

5. (Original) The method of claim 4, wherein the ocular tissue is selected from the group consisting of retina, macula and cornea.

Claims 6-8 (Canceled).

9. (Original) The method of claim 1, wherein the tissue comprises a neoplasm.

10. (Original) The method of claim 9, wherein the neoplasm is a malignant neoplasm.

11. (Original) The method of claim 10, wherein the malignant neoplasm is a metastatic malignant neoplasm.

12. (Original) The method of claim 10, wherein the malignant neoplasm is a carcinoma.

Claims 13-14 (Canceled).

15. (Previously presented) The method of claim 1, wherein the agent comprises an $\alpha 5\beta 1$ integrin binding fragment of said antibody.

Claims 16-18 (Canceled).

19. (Original) The method of claim 1, wherein the agent is linked to a cytotoxin.

20. (Original) The method of claim 19, wherein the cytotoxin is a cancer chemotherapeutic drug.

Claims 21-79 (Canceled).

Claims 80-85 (Canceled).

86. (Previously presented) The method of claim 1, wherein said tissue is in a human subject.

87. (Previously presented) The method of claim 10, wherein said malignant neoplasm is selected from the group consisting of a sarcoma, a mesothelioma, a teratocarcinoma, an astrocytoma, and a glioblastoma.

88. (Previously presented) The method of claim 12, wherein said carcinoma is selected from the group consisting of a breast carcinoma, a colon carcinoma, an ovarian carcinoma and a pancreatic carcinoma.

Claims 89-120. (Canceled)